Back to News
Market Impact: 0.25
Clene Announces $4M Registered Direct Offering; Funding Expected Through Q1 2027
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Clene Inc. priced a $4 million registered direct equity offering of 1,219,513 shares at $3.28 per share. The financing provides capital for the clinical-stage ALS and neurodegenerative-disease developer but may dilute existing shareholders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
CLNN-0.45
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Intel’s stock crashes, knocking $12B from government’s stake
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools